A state of T-cell activation, reflected by a marked degree of spontaneous proliferation in vitro, exists among patients with human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) but not in those with retroviral-induced adult T-cell leukemia (ATL). We wished to define the mechanism by which the immune activation of circulating cells from HAM/ TSP is driven, thus gaining insight into the pathogenesis of this HTLV-I-associated disease. By using a modification of the polymerase chain reaction, we compared the levels ofinterleukin 2 (IL-2) and IL-2 receptor a chain (IL-2Ra) mRNA expression to the transcription of the HTLV-I transactivator gene, pX, in peripheral blood mononuclear cells of HAM/TSP and ATL patients as well as seropositive carriers. Up-regulation of IL-2 and IL-2Ra transcripts was detected in HAM/TSP and seropositive carriers that paralleled the coordinate mRNA expression of the pX transactivator. In addition, IL-2 and soluble IL-2Ra serum levels in HAM/TSP and seropositive carriers were elevated. Despite markedly elevated levels of soluble IL2Ra in ATL, transcripts for IL-2 and pX were not demonstrable in the circulating cells. Finally, the marked degree of in vitro spontaneous proliferation present in HAM/TSP was profoundly inhibited by specific anti-IL-2R or anti-IL-2 blocking antibodies.
Infection with the human T-cell lymphotropic virus type I (fiTLV-I) is associated with a chronic progressive myelopathy described in the Caribbean basin as tropical spastic paraparesis (TSP) (1, 2) . A similar condition termed HTLV-I-associated myelopathy is endemic in Japan (3) . It is now recognized that HTLV-I-associated myelopathy and tropical spastic paraparesis (HAM/TSP) are equivalent clinical conditions (4) . In addition, the retrovirus associated with HAM/ TSP is nearly identical to prototype HTLV-I derived from patients with a malignant clonal proliferation of mature T cells known as adult T-cell leukemia (ATL) (5) (6) (7) (8) . However, the mechanism by which HTLV-I infection contributes to the pathogenesis of HAM/TSP is unknown. It has been proposed that the panoply of disease states associated with HTLV-I infection may result from the expression of a unique sequence called pX within the proviral genome (9) . pX encodes a transcriptional activator known as Tax, which has been shown in vitro to induce a variety of host cellular genes including interleukin 2 (IL-2) and the a chain of the IL-2 receptor (IL-2Ra) (10, 11) . This altered regulation of cellular genes by the pX transactivating element may begin a process of T-cell activation and proliferation with subsequent events leading to inflammatory nervous system damage in HAM/ TSP or malignant transformation in ATL. Recent findings suggest that immune activation may contribute to the histopathological changes in HAM/TSP. Mononuclear inflammatory lesions are observed in the central nervous system with lymphocytic perivascular cuffing (12, 13) . In addition, the neurological abnormalities are frequently associated with an altered T-cell phenotype consisting of an increased CD4+/ CD8' ratio and a high proportion of IL-2Ra' (CD25+) cells in the peripheral blood (14, 15) . The foremost evidence that an ongoing state of lymphocyte activation exists in patients with HAM/TSP is the marked propensity for their circulating mononuclear cells to spontaneously proliferate in vitro (16, 17) . Although a lesser degree of spontaneous proliferation is noted in HTLV-I-seropositive carriers (16) , no such proliferative response has been observed in the circulating cells from ATL patients (18 (21, 22) .
PCR. Oligonucleotide primers and probes were synthesized by the phosphoramidite method (23) . Amplification of pX mRNA was achieved with oligonucleotide primers derived from the long terminal repeat and pX domains, pX/1 and pX/2, respectively (see Fig. 1 ). The target sequence defined by these primers includes all three regions of the doubly spliced pX transactivating element. pX cDNA synthesis was performed with the pX/2 primer to direct pXspecific first-strand synthesis. Total RNA (5-10 ,g) from patient cells or primer, and 1.0 p.M pX/2 primer, and 0.01% gelatin, heated to 94°C for 5 min, quenched on ice, and supplemented with 5 units of Thermus aquaticus polymerase (Perkin-Elmer/ Cetus). Samples were subjected to 40 cycles of amplification consisting of denaturation for 1 min at 94°C, primer annealing for 1 min at 53°C, and polymerization for 2 min at 72°C. An actin-targeted gene sequence served as an internal test control and was defined by 5'-TTCTACAATGAGCTGCGTGT-3' and 5'-GCCAGACAGCACTGTGTTGG-3', sense and antisense primers, respectively, and the amplified 636-base-pair (bp) actin signal was detected by an internal 40-base probe, 5'-ACTACCTCATGAAGATCCTCACCGAGCGCGGCTA- . In a similar manner, IL-2, IL-2Ra, and actin mRNA sequences were reverse-transcribed and amplified together for 30 cycles in a "multiplex" PCR from 1 ,ug of total RNA samples (see Figs. 2 and 3 ).
Liquid and Southern Blot Hybridization. For rapid identification, 30-,ul samples from each reaction mixture were liquid-hybridized (25) with purified 32P-end-labeled oligonucleotide probes (26) , electrophoresed on a 5% polyacrylamide gel, and the gel-retardation preparations were autoradiographed. Further confirmation of the nature of the amplified sequence was obtained from sizing analysis by Southern blot hybridization as follows: 20 pL. of each PCR reaction mixture was electrophoresed through a 1% agarose gel and then blot-transferred onto a nitrocellulose filter. Filters were baked at 800C for 1 hr, prehybridized in a previously de- scribed buffer (27) , and hybridized overnight at 60'C with 4.5 ml of buffer containing one of the following 32P-labeled nick-translated DNA probes (1 x 107 dpm/ml): a 9-kilobase (kb) Sac I clone of the HTLV-I provirus (MT-2, obtained from F. Wong-Staal, National Institutes of Health), a 2.3-kb EcoRI full-length cDNA clone of IL-2R (pIL-2R3, obtained from W. Leonard, National Institutes of Health), and a 0.71-kb HindIII-Pst I cDNA clone of human IL-2 (paw55, obtained from the American Type Culture Collection). Filters were washed (27) and autoradiographed at -70'C.
IL-2/IL-2R Assays. Heparinized plasma samples were incubated in 2.8% CaCI2 (1:9 dilution with plasma) for 2 hr at 370C and then centrifuged at 1000 x g for 15 min to remove fibrin. Sera or treated plasma test samples were diluted 1:3 with isotonic phosphate-buffered saline and assayed for IL-2 in duplicate with a commercial ELISA kit (Intertest 2, Genzyme). A standard curve of recombinant human IL-2 ranging from 62.5 units/ml to 1.0 unit/ml and containing the same percentage of serum/plasma as the test samples was included in each assay. The mean (± SEM) IL-2 concentration was calculated and expressed in units/ml, with 1 unit representing 0.33 ng. Circulating soluble IL-2R levels were measured using a sandwich ELISA (28) . The 3 . Southern hybridization for the detection of cellular IL2Ra expression. Total RNA from patients with ATL and HAM/TSP, seropositive carriers, and normal controls was subjected to IL2Ra-specific reverse transcription and then PCR amplification as in Fig. 2 with the addition of IL-2Ra-specific primers corresponding to regions within exons 1 and 8, IL-2Ra/1 (5'-GATTCATACCTGCT-GATGTG-3') and IL-2Ra/8 (5'-GATTGTTCTICTACTC1TCC-3'), respectively (33) . These primers directed amplification of an 813-bp signal within the IL-2Ra mRNA, which was detected with an oligonucleotide probe derived from exon 2 (5'-GAGCTCTGTGAC-GATGACCCGCCAGAGATCCCACACGCCACA-3'). This 813-bp signal representing IL-2Ra mRNA was detected after transfer of the PCR products to a nitrocellulose filter and hybridization of the blot with a 2.3-kb cDNA probe for IL-2Ra. A representative actin sequence, amplified in the same reaction vial as IL-2Ra from each RNA sample, is shown directly below the respective lanes.
ucts, we measured the levels of IL-2 and the soluble form of IL-2R in HAM/TSP, ATL, seropositive carrier, and normal control serum/plasma samples. IL-2 levels in HAM/TSP (12.7 ± 5.1 units/ml) and seropositive carriers (16.6 ± 8.2 units/ml) were significantly elevated (P < 0.05) above healthy controls (0.5 ± 0.4 unit/ml). Paralleling the absence of detectable IL-2 transcripts by PCR, there was no measurable IL-2 in eight ATL serum samples. In contrast, very high levels of soluble IL-2R were present in these same ATL samples (117,200 ± 30,600 units/ml). In addition, modest but significantly elevated soluble IL-2R levels were detected in the HAM/TSP patients (1100 ± 220 units/ml, P < 0.00001) and seropositive carriers (600 ± 100 units/ml, P < 0.01) as compared to healthy controls (290 ± 20 units/ml).
To better characterize the lymphoproliferative response in HAM/TSP and seropositive carriers, peripheral mononuclear cells were cultured in the presence of specific antibodies that block the interaction of IL-2 with its binding peptides, the a and ,B chains of the IL-2 receptor (Fig. 4) . The circulating cells from all HAM/TSP patients displayed a marked degree of spontaneous proliferation, assessed by a [3H]thymidine uptake of 40,200 + 6200 cpm after 6 days in medium alone compared to 690 ± 70 cpm for normal individuals. Addition of anti-Tac, Mik81, or an IL-2-neutralizing antibody produced a profound inhibition of the proliferative response [40, 200 cpm to 4500 ± 2200 cpm (P < 0.001 for anti-Tac), to 10,800 ± 3100 cpm (P < 0.05 for MikB1), and to 2300 ± 1000 cpm (P < 0.001 for anti-IL-2)]. This inhibitory effect from blocking binding of IL-2 to its receptor appeared specific, as the addition of irrelevant monoclonal antibody produced no meaningful suppression of proliferation. Moreover, the combination of anti-Tac and Mikffl completely abrogated the augmented HAM/TSP proliferation. Although an increased proliferative response was demonstrated in seropositive carriers (7700 ± 1300 cpm, P < 0.05) as compared to healthy controls (690 ± 70 cpm), it was significantly less than in HAM/TSP (P < 0.01). However, a similar inhibition of spontaneous proliferation was observed when circulating cells from seropositive carriers were cultured in the presence of anti-Tac (1100 ± 300 cpm, P < 0.05), anti-IL-2 antibody (1800 ± 500 cpm, P < 0.05), or the combination of anti-Tac and MikP1 (1000 ± 300 cpm, P < 0.05). Finally, no spontaneous proliferation was observed in the ATL patients (1200 ± 500 cpm). 
DISCUSSION
The mechanism by which HTLV-I infection causes an inflammatory and demyelinating neurologic process in its host is unknown but is thought to be related to an aberrant activation of T cells in HAM/TSP, reflected by an increased percentage of circulating IL-2R' cells in HAM/TSP (14) and an enhanced proliferative response from the unstimulated lymphocytes of these patients (16, 17) . The initiation of such a T-cell response appears to be critically dependent on the sequential induction of IL-2 and IL-2Ra and the subsequent binding of IL-2 to its high-affinity receptor. An analysis of the HTLV-I-transactivating gene pX suggests a potential mechanism to explain how infection with HTLV-I might drive this chain of events. Cotransfection studies involving the insertion of a pX cDNA into resting Jurkat T cells revealed that the retroviral transactivating gene product is capable of increasing the transcription of host genes governing human IL-2/IL-2Ra expression (10, 11) . Thus, the expression of pX in vivo could be essential for maintaining a state of lymphocyte activation in HAM/TSP, thereby contributing to the pathogenesis of this disease. However, by using conventional Northern blot analysis, we have failed to detect pX mRNA in the freshly isolated peripheral mononuclear cells of HAM/ TSP patients (C.L.T., unpublished data). Therefore, we employed a highly sensitive, yet specific, PCR (6) and may be reflected in vitro by the spontaneous proliferative responses that others (16, 17) have observed and we have confirmed. Furthermore, the activated T cells in seropositive carriers would then be primed for a second undefined event that would ultimately result in leukemogenesis with a clonal population of IL-2-independent ATL cells (34) . Although not in accord with our findings, a pX transcript was detected in fresh mononuclear cells of Japanese patients with ATL (35) . Differences in PCR methodologies, pertaining to the reversetranscription step and to the cDNA sequences targeted in the subsequent gene amplification steps, may account for the discrepancy. Furthermore, the level of pX expression may vary due to differences between Japanese and Caribbean ATL populations studied. Nevertheless, in a subset of ATL patients, we demonstrated pX mRNA in freshly biopsied malignant lymph nodes (36) . Therefore, we believe that in ATL pX gene expression may be important in the early stages of leukemogenesis or in certain microenvironments where there is high cell turnover. For the majority of ATL patients in advanced stages of disease an extraordinarily sensitive PCR technique may be necessary to detect pX mRNA in circulating cells. However, it is important to consider the possibility that such a high level of sensitivity permits detection of retroviral transcripts expressed from the smaller polyclonally infected T-cell population, even though retroviral mRNA expression may not be representative of the larger leukemic clone. This view is supported by the experience of establishing cell lines from ATL patients in which, for 70% of the results, a nonleukemic clone predominates (T.A.W., unpublished data). Therefore, the quantitative differences in pX expression in HAM/TSP and ATL patients and seropositive carriers demonstrated with our approach may offer a more realistic assessment of the pathogenic role of pX transcription in HTLV-I-associated disorders.
The data were derived from patient population comparisons, and vertical intrapatient analyses were not performed. Therefore, we were unable to directly study the relationship of pX expression to the production of IL-2 and IL-2Ra or to the degree of spontaneous proliferation within individual patients from a given population group. However, the HAM/ TSP patient and seropositive carrier in which we were unable to detect mRNA for the pX gene (lanes 2 in the respective categories from Fig. 1 HAM/TSP-associated HLA haplotypes were found in 70% of Japanese patients with HAM/TSP but not in any individuals with ATL (37) . Peripheral blood lymphocytes bearing the HAM/TSP-associated haplotypes exhibited a high immune response to HTLV-I antigen whereas the ATL-associated haplotypes had a low response. Since the combination of immune activation and genetic predisposition may contribute to the mononuclear inflammation and demyelination present in the central nervous system of HAM/TSP patients, downmodulating this process provides a rationale for therapy with immunosuppressive agents. A role for immune intervention in HAM/TSP is supported by the observation that treatment with oral prednisolone has been associated with clinical improvement in many cases (38) . However, others have reported less consistent effects with corticosteroids (39) . Unfortunately, its long-term use in a chronic illness, such as HAM/TSP, can produce serious complications. We have, therefore, turned to the IL-2R as a target for immunotherapy in patients with HAM/TSP. The foundation for such an approach is the observation that an increased proportion of circulating cells from HAM/TSP patients express surface-bound IL-2Ra, identified by the anti-Tac monoclonal antibody, whereas normal resting cells do not (14) . Furthermore, we have shown that in vitro anti-Tac treatment of peripheral mononuclear cells from HAM/TSP patients mark6dly inhibits spontaneous proliferative responses. In addition, anti-Tac therapy has recently been safely and effectively utilized in humans for the treatment of ATL (40) and the prevention of allograft rejection (41) . In a similar fashion, anti-Tac may suppress the immune activation in HAM/TSP and potentially ameliorate the inflammatory process leading to nervous tissue damage in this disease.
